<unk>  is indicated for the treatment of adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen. On August 17, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to<unk>  for adults with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
Dostarlimab
Bezlotoxumab
Tralokinumab
Sacituzumab govitecan
Teprotumumab
Tisotumab vedotin
Ustekinumab
Evolocumab